Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro
Authors: Zhi-hong Zheng
Li-guang Lou
Jian-hua Xu
Yang Liu
Li-xian Wu
Rui-jia Chen
Yuan-zhong Chen
Ying Wu
Li-sen Huang
Journal: Acta Pharmacologica Sinica (2014)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: kinase inhibitors; imatinib resistance; chronic myeloid leukemia; C817; curcumin derivative
Affiliations: 1] Department of Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [3] Fuijan Key Laboratory of Natural Medicine Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China., 1] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Fuijan Key Laboratory of Natural Medicine Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China., 1] Department of Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China., 1] Institute of Materia Medica, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [2] Fuijan Key Laboratory of Natural Medicine Pharmacology, School of pharmacy, Fujian Medical University, Fuzhou 350004, China [3] Department of pharmacochemistry, School of pharmacy, Fujian Medical University, Fuzhou 350004, China., Shanghai Institute of Materia Medica, Shanghai 201203, China., Fujian Institute of Hematology, Union Hospital, Fujian Medical University, Fuzhou 350001, China.

Abstract:  Aim: To find new kinase inhibitors that overcome the imatinib resistance in treatment of chronic myeloid leukemia (CML), we synthesized C817, a novel derivative of curcumin, and tested its activities against wild-type (WT) and imatinib-resistant mutant Abl kinases, as well as in imatinib-sensitive and resistant CML cells in vitro. Methods: 32D cells harboring WT or mutant Abl kinases (nucleotide binding P-loop mutants Q252H, Y253F, and imatinib contact residue mutant T315I), as well as K562/G01 cells (with whole Bcr-Abl gene amplication) were tested. Kinase activity was measured using Kinase-Glo Luminescent Kinase Assay Platform in recombinant WT and mutant (Q252H, Y253F, and T315I) Abl kinases. Cell proliferation and apoptosis were examined using MTT assay and flow cytometry, respectively. The phosphorylation levels of Bcr-Abl initiated signaling proteins were analyzed using Western blotting. Colony forming units (CFU) growth and long term culture-initiating cells (LTC-ICs) were used to test the effects of C817 on human leukemia progenitor/stem cells. Results: C817 potently inhibited both WT and mutant (Q252H, Y253F, and T315I) Abl kinase activities in a non-ATP competitive manner with the values of IC₅₀ at low nanomole levels. In consistent with above results, C817 suppressed the growth of both imatinib-sensitive and resistant CML cells, including wild-type K562, K562/G01, 32D-T315I, 32D-Q252H, and 32D-Y253F cells with the values of IC₅₀ at low micromole levels. C817 (0.5 or 1 μmol/L) dose-dependently inhibited the phosphorylation of Bcr-Abl and downstream proteins STAT-5 and CrkL in imatinib-resistant K562/G01 cells. Furthermore, C817 significantly suppressed CFU growth and LTC-ICs, implicating that C817 could eradiate human leukemia progenitor/stem cells. Conclusion: C817 is a promising compound for treatment of CML patients with Bcr-Abl kinase domain mutations that confer imatinib resistance. 

Retracted: No

PubPeer comments:
 Figure 3A. One of the panels appears to show repetitive features. ![file] Here is a close-up of that panel: ![file] , 
 Thanks to Dr. Bik for asking questions about the image in this paper. C817 induced apoptosis of leukemia cells is a result that can be easily repeated. This image is automatically generated by flow cytometry, so we don t know why there are similar dots. We will check the original records and try to find out the reasons for the similarity of some small dots. Thank you! ,